Drug Database
ME

methyldopa

✓ Approved

Merck & Co. · 小分子 · 小分子

什么是 methyldopa?

methyldopa 是一种小分子,由Merck & Co.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

公司Merck & Co.
药物类别小分子
给药途径Oral (PO)
状态Approved

治疗适应症

methyldopa 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedJournal of clinical medicine2026-11-14

Methyldopa-Induced Autoimmune Antibodies in Pregnant Women-Case Series and Literature Review.

Grycuk Wiktoria W, Pach Magdalena M, Massalska Diana D

Background: Methyldopa is widely used for the treatment of hypertension during pregnancy because of its established maternal and fetal safety profile. However, it can induce red blood cell autoantibodies, occasionally resulting in autoimmune hemolytic anemia. The aim of this study was to summarize current evidence on methyldopa-associated red blood cell autoantibody formation and autoimmune hemolytic anemia in pregnant women, based on a review of the available literature and observations from our center. Methods: A scoping review was conducted using the PubMed/MEDLINE, Web of Science, and Scopus databases to identify studies addressing autoimmune antibodies or hemolytic anemia associated with methyldopa therapy in pregnancy. Two independent reviewers screened titles and abstracts and assessed full-text articles for eligibility. Disagreements were resolved through discussion with a third reviewer. In addition, citation mapping was performed using the Litmaps tool (Litmaps Ltd.) to expand the set of relevant studies. In addition to the literature findings, two cases from our center, consistent with the scope of this review, were included in the study. Results: Four studies met the inclusion criteria, all of which were case-based. In addition, two cases from our center were included. The available data on six pregnancies suggest that methyldopa may induce the production of autoantibodies with variable clinical expression-most often asymptomatic, although in some cases hemolytic anemia may occur. These autoantibodies can cross the placenta. Neonatal outcomes are likewise heterogeneous, ranging from asymptomatic presentations to hemolysis with associated jaundice. Conclusions: Methyldopa-induced autoantibody formation in pregnancy is often a benign finding; however, it requires careful evaluation to exclude hemolytic anemia. Drug discontinuation appears effective in symptomatic patients, whereas management of asymptomatic cases is not well defined and should be individualized. Further studies are needed to clarify the incidence and guide clinical management.

PMID 43030883
阅读全文 →
PubMedClinical parkinsonism & related disorders2026-11-13

Non-motor outcomes and divergent plasma metabolite changes during continuous subcutaneous foslevodopa/foscarbidopa infusion in Parkinson's disease.

Igari Kota K, Fujimaki Motoki M, Fujimoto Masataka M, Kaga Naoko N et al.

Circulating levodopa and metabolite changes during transition to continuous subcutaneous foslevodopa/foscarbidopa infusion (CSCI), and their relationships with clinical outcomes, remain incompletely characterized. In this exploratory prospective observational study, 19 patients with advanced Parkinson's disease underwent clinical assessments and fasting morning plasma sampling before CSCI and after clinically judged dose stabilization. Concentration-outcome associations were examined in exploratory post hoc analyses. At a mean of 16.2 days, median Movement Disorder Society Non-Motor Rating Scale total and gastrointestinal scores decreased from 96 to 80 and 5 to 2 (adjusted P = 0.036 and 0.005); quality of life improved. Mean levodopa and 3-O-methyldopa increased 2.8-fold and 3.2-fold (both adjusted P < 0.001), whereas median free dopamine and 3,4-dihydroxyphenylacetic acid decreased from 10.1 to 5.2 and 575 to 248 nM (adjusted P = 0.003 and 0.021). The exploratory pretreatment dopamine coefficient in the baseline-score-adjusted non-motor model was -3.06 points/nM (95% confidence interval, -6.13 to 0.01; P = 0.051). Larger dopamine reductions were associated with lower baseline-adjusted on-treatment gastrointestinal scores, with attenuation in the catechol-O-methyltransferase (COMT)-related sensitivity cohort. Heteroskedasticity-robust confidence intervals for both dopamine coefficients included zero. These findings describe concentration changes during transition to a CSCI-based regimen. Dopamine-clinical associations were exploratory; predictive utility and causal mediation were not established.Registration: UMIN000054567, registered 4 June 2024 (retrospectively).

PMID 43022397
阅读全文 →
PubMedHypertension research : official journal of the Japanese Society of Hypertension2026-11-05

Blood pressure response to methyldopa as a potential indicator of renal denervation responsiveness in resistant hypertension: a case report.

Matsuo Miki M, Horinouchi Hiroki H, Asaumi Yasuhide Y, Sonoura Takuryu T et al.

PMID 42982993
阅读全文 →
PubMedActa pharmaceutica Sinica. B2026-10-28

Antihypertensive drug-induced liver injury is rare, but strongly associated with HLA-B∗35:01.

Dara Lily L, Nicoletti Paola P, Majeed Chaudry Nasir CN, Dellinger Andrew A et al.

Anti-hypertensive (anti-HTN) drugs are widely prescribed, but the features of associated drug-induced liver injury (DILI) are poorly defined. A total of 2207 patients enrolled in the Drug-Induced Liver Injury Network (DILIN) from 2003 to 2024 were adjudicated as definite, highly likely, or probable DILI. Of these, 44 cases were attributed to anti-HTN drugs. These were compared with non-anti-HTN DILI cases and population controls. Human Leukocyte Antigen (HLA) sequencing was performed, and allele frequencies were analyzed using Fisher's Exact Test. Among the 44 anti-HTN DILI cases, 14 were caused by ACE inhibitors/ARBs, 13 by methyldopa, 11 by hydralazine, and 3 each by beta-blockers and calcium-channel blockers. Methyldopa DILI presented with hepatocellular injury in young women (prescribed mainly for pregnancy-related HTN). Non-methyldopa cases were 60% hepatocellular, 28% cholestatic, and 9% mixed. Severe outcomes included two liver transplants and two deaths (lisinopril and hydralazine). HLA-B∗35:01 was markedly enriched (50% vs. 13% in controls; OR 6.0; P = 1 × 10-8) and was linked to shorter latency (50 vs. 109 days; P = 0.02) but not severity. HLA-B∗35:01 was overrepresented across all drug classes, including 66% of methyldopa cases, 27% of hydralazine cases, and 42% of ACE/ARB cases. DILI from anti-HTN medications is very rare but strongly associated with HLA-B∗35:01, especially for methyldopa. Carriers display a shorter latency, potentially indicating an accelerated adaptive immune response, that warrants further exploration.

PMID 42948728
阅读全文 →
PubMedInternational journal of molecular sciences2026-10-16

Maternal Gestational Hypertension Is Associated with Reduced TSG-6 in Human Milk: Potential Implications for Neonatal Immunological Support.

Przywara Dominika D, Kondracka Adrianna A, Petniak Alicja A, Słyk-Gulewska Patrycja P et al.

Tumor necrosis factor alpha-stimulated protein 6 (TSG-6) is a potent anti-inflammatory mediator secreted by mesenchymal stem cells (MSCs). In human milk (HM), these cells (human milk mesenchymal stem cells, HM-MSCs) contribute to postnatal programming of the neonatal gastrointestinal immune axis. This study assessed how maternal gestational hypertension and maternal age affect the cytoprotective TSG-6 pool and its associated immunomodulatory microRNA signature in early milk. Early colostrum, 2-4 days postpartum, from healthy mothers and hypertensive patients was analyzed. TSG-6 gene expression in the heterogeneous milk cellular fraction containing HM-MSCs and TSG-6 protein concentration in whole milk were determined using quantitative polymerase chain reaction (qPCR) and Enzyme-Linked Immunosorbent Assay (ELISA), respectively. Comprehensive multivariable General Linear Models (GLMs) were used to adjust for potential confounding variables, including pre-pregnancy Body Mass Index (BMI), gestational age (GA), and gestational diabetes. Additionally, TSG-6 levels were correlated with fetal cord blood gas parameters and previously profiled microRNAs in the cellular fraction. GLM analysis revealed that gestational hypertension remained significantly associated with reduced TSG-6 gene expression in the cellular fraction and total TSG-6 protein concentration in whole milk, regardless of pre-pregnancy BMI or metabolic comorbidities. In healthy pregnancies, exploratory analyses suggested that TSG-6 levels correlated positively with optimal fetal metabolic status (cord blood pH). Importantly, TSG-6 expression showed a strong positive correlation with a signature of immunomodulatory microRNAs (miR) (miR-155-5p, miR-21-3p, miR-126-3p). These microRNAs were concurrently downregulated in the hypertensive group; however, because all hypertensive participants received methyldopa, the independent contributions of hypertension and antihypertensive treatment to these changes cannot be distinguished. Gestational hypertension independently reduces the anti-inflammatory TSG-6 in early breast milk. The concomitant reduction in TSG-6 and its correlated microRNA co-expression pattern indicates an altered immunomodulatory profile within the mammary gland during lactation. We hypothesize that these changes might alter the local immunomodulatory properties of milk in the neonatal gastrointestinal tract. However, because no functional in vitro or in vivo assays were performed, this remains a purely theoretical implication that requires future experimental validation.

PMID 42883820
阅读全文 →
PubMedIndian journal of psychiatry2026-09-30

Presumptive false-positive amphetamine urine screen in a pregnant woman receiving α-methyldopa: A case report.

Sayer Ömer Naim ÖN, Baytar Gamze G, Kılıç Hülya H, Soytürk Koray K

PMID 42812858
阅读全文 →

注册免费账户还可查看另外 2927 篇文献

免费注册查看全部文献 →

了解更多methyldopa